Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AdAPT-001 oncolytic adenovirus shows promising phase 1 cancer treatment results

By Brian Buntz | June 8, 2023

adapt-001

Rendering of AdAPT-001

Oncolytic adenoviruses have won significant attention in recent years as a novel approach to cancer treatment. One example of the trend is AdAPT-001 TGF-ß Trap, an engineered variant of the common cold virus equipped with a transforming growth factor-beta (TGF-β) “trap.” This mechanism is designed to latch onto and neutralize TGF-β, an immunosuppressive cytokine involved in cancer cell growth and disease progression.

At the 2023 ASCO Annual Meeting, the developer of AdAPT-001, EpicentRx, shared initial findings from a phase 1 trial on AdAPT-001. The initial data indicates that patients generally tolerate AdAPT-001 well.

So far, the study has enrolled 28 patients for treatment with AdAPT-001 as a single agent. EpicentRx plans to enroll an additional roughly 50 patients for a phase 2 portion where AdAPT-001 will be combined with immunotherapy.

In the phase 1 portion, the most common side effects were local inflammation, fever and fatigue. There were no reported instances of dose-limiting toxicities, grade 4 toxicities or treatment-related serious adverse events.

Phase 1 results for AdAPT-001 shared at the 2023 ASCO Annual Meeting

Promising phase 1 results revealed for AdAPT-001 oncolytic adenovirus

Distribution of treatment responses in the 28 patients enrolled in the phase 1 trial of the AdAPT-001 oncolytic adenovirus.

In a presentation at ASCO, the company highlighted encouraging signs of biological activity such as virus replication and tumor shrinkage. While some patients showed stable or progressive disease, others experienced durable stable disease for more than six months or demonstrated an ‘abscopal response,’ a systemic immune reaction that occurs when radiation therapy or another localized treatment not only reduces the size of a targeted tumor but also results in the shrinkage of untreated tumors elsewhere in the body.

Next steps for the AdAPT-001 cancer treatment candidate

Following the positive results, researchers plan to advance the compound to phase 2 trials, where it will be administered at a dose of 1.0 x 10¹² viral particles biweekly.

Dr. Anthony Paul Conley from the University of Texas MD Anderson Cancer Center in Houston, Texas led the study in partnership with a team of researchers from various research institutions. The trial began on March 29, 2021.

The phase 1 portion kicked off with a 3 + 3 dose escalation safety run-in design to gradually increase the dosage while monitoring patient safety. The trial then shifted into a dose expansion single-agent protocol, where researchers tested the drug as a standalone treatment. The trial concluded with an expansion single agent plus checkpoint inhibitor phase, exploring the potential synergistic effects of combining AdAPT-001 with a checkpoint inhibitor.

In recent years, there has been a growing amount of preclinical and clinical development of naturally occurring and genetically engineered oncolytic viruses, yielding encouraging data, as a recent article in Signal Transduction and Targeted Therapy noted. The promising results of the phase 1 AdAPT-001 study of an oncolytic adenovirus further underscore the potential of ongoing oncolytic virotherapy research for cancer treatment.


Filed Under: Cell & gene therapy, clinical trials, Drug Discovery, Infectious Disease, Oncology
Tagged With: AdAPT-001, ASCO Annual Meeting, Cancer treatment, immunotherapy, Oncolytic adenovirus, Phase 1 trial, TGF-β trap
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Comments

  1. echohan999@gmail.com says

    July 18, 2023 at 8:18 am

    Thanks for the post, which is quite insightful!

    Oncolytic adenoviruses (Ads) have emerged as a promising therapeutic tool to provide a versatile system for gene expression studies and therapeutic applications.

Related Articles Read More >

AP Biosciences charts course for safer CD137 bispecifics with its T-cube platform
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Why smaller, simpler molecular glues are gaining attention in drug discovery
Technology background. Big data concept. Binary computer code. Vector illustration.
COTA Healthcare announces AI milestone in real-world oncology data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE